The Kidney Cancer Research Consortium is funded via a Department of Defense grant.
CLINICAL TRIALS
  • Home
  • About
  • Why KCRC
    • Research Leadership
    • What We Offer
    • How We Help
  • Clinical Trials
  • For Patients
  • News
  • Contact

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

by Liz Hanson | Aug 18, 2021 | Uncategorized

FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

by Liz Hanson | Aug 13, 2021 | Uncategorized

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021


info@kidneycancerconsortium.org

M. Roserika Brooks, MS, CCRP
Administrative Director,
KCRC Coordinating Center
(713) 792-2731
1155 Pressler Street
Houston, Texas 77030

Contact Us

"*" indicates required fields

Name*

Copyright © 2023 Kidney Cancer Research Consortium. Website design by Type A Virtual Solutions.